Plain-English translation of NCT06420375 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a new drug called can help treat mild ulcerative colitis—a condition where the colon becomes inflamed and causes pain, diarrhea, and bleeding. You would take this medication for 4 weeks, then switch to a placebo (a pill with no active ingredient) for another 4 weeks to see how the treatment works compared to no treatment. The study will last 12 weeks total.
Current treatments for ulcerative colitis don't work for everyone, and doctors need new options to help people control their symptoms and reduce inflammation. This trial is testing whether this medication could be a helpful new choice for patients who aren't getting enough relief from existing treatments.
You likely qualify if…
You likely don't qualify if…
You would visit the study site 7 times over 12 weeks. You would take the study medication by mouth twice a day for 4 weeks, then switch to placebo for 4 weeks (in random order), along with a butyrate supplement. Some participants may also receive one IV dose of the medication. You'll keep a log of your doses, give blood samples, and provide stool and urine samples at various visits so the researchers can track how the treatment is working.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States